Beginning June 1, 2024, eligible patients will pay no more than $35 a month at retail pharmacies for all Boehringer Ingelheim inhalers to treat asthma and chronic obstructive pulmonary disease (COPD). Included are:
The company said in a press release that it will decrease the list price on some of its inhaler products and will continue providing rebates off the list price of its medicines to insurers and pharmacy benefits managers.